Nektar Therapeutics’s recently made public that its Chief Legal Officer Wilson Mark Andrew unloaded Company’s shares for reported $30062.0 on Dec 23 ’24. In the deal valued at $0.90 per share,33,402 shares were sold. As a result of this transaction, Wilson Mark Andrew now holds 351,892 shares worth roughly $0.29 million.
Then, Wilson Mark Andrew sold 16,560 shares, generating $14,738 in total proceeds. Upon selling the shares at $0.89, the Chief Legal Officer now owns 335,332 shares.
Before that, Wilson Mark Andrew bought 16,560 shares. Nektar Therapeutics shares valued at $14,801 were divested by the Officer at a price of $0.89 per share.
B. Riley Securities initiated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on January 08, 2025; the price target was $4. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Piper Sandler began covering NKTR with “an Overweight” recommendation on November 04, 2024.
Price Performance Review of NKTR
On Monday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -2.22% to $0.81. Over the last five days, the stock has lost -7.60%. Nektar Therapeutics shares have fallen nearly -13.02% since the year began. Nevertheless, the stocks have risen 49.16% over the past one year. While a 52-week high of $1.93 was reached on 01/07/25, a 52-week low of $0.52 was recorded on 01/29/25. SMA at 50 days reached $0.9814, while 200 days put it at $1.2458.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 0.7880, which if violated will result in even more drops to 0.7670. On the upside, there is a resistance level at 0.8432. A further resistance level may holdings at 0.8774. The Relative Strength Index (RSI) on the 14-day chart is 32.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0446, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.37%. Stochastics %K at 11.13% indicates the stock is a buying.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2025-01-15, growing by 0.32 million shares to a total of 4.72 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 4.4 million shares. There was a rise of 6.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 28, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $2 price target.
